Will osteopontin bridge the gap towards clinical application in chronic kidney disease?
- PMID: 36941130
- PMCID: PMC10229269
- DOI: 10.1093/ndt/gfad057
Will osteopontin bridge the gap towards clinical application in chronic kidney disease?
Conflict of interest statement
M.H.d.B. has served as a consultant, received honoraria or research support (all to employer) from Amgen, Astra Zeneca, Bayer, Kyowa Kirin Pharma, Pharmacosmos, Sanofi Genzyme and Vifor Pharma. J.J.C. has received research support from Amgen, AstraZeneca, Astellas, Vifor Pharma, and Novonordisk; and speaker or advisory board fees from AstraZeneca, Baxter, GSK, Abbott, and Fresenius.
Comment on
-
Association of osteopontin with kidney function and kidney failure in chronic kidney disease patients: the GCKD study.Nephrol Dial Transplant. 2023 May 31;38(6):1430-1438. doi: 10.1093/ndt/gfac173. Nephrol Dial Transplant. 2023. PMID: 35524694
References
-
- Foreman KJ, Marquez N, Dolgert Aet al. . Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet North Am Ed 2018;392:2052–90. 10.1016/S0140-6736(18)31694-5. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
